gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Mycophenolate Mofetil or Mycophenolate Sodium as treatment option in Birdshot-Chorioretinopathyn

Meeting Abstract

  • Nicole Stübiger - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin
  • D. Doycheva - University Eye Clinic Tübingen
  • C. M. E. Deuter - University Eye Clinic Tübingen
  • S. Winterhalter - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Virchow Clinic and Campus Benjamin Franklin, Berlin
  • M. Zierhut - University Eye Clinic Tübingen

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg23

DOI: 10.3205/10rg23, URN: urn:nbn:de:0183-10rg235

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2010/10rg23.shtml

Published: September 21, 2010

© 2010 Stübiger et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Purpose: To evaluate the outcome of patients with birdshot retinochoroidopathy (BRC) treated with with mycophenolate mofetil (MMF, CellCept®) or mycophenolate sodium (MPS, Myfortic®).

Methods: We retrospectively reviewed the medical charts of patients with BRC who were treated with MMF or MPS and were evaluated consecutively over a 27-year period.

Results: Fourteen BRC patients (ratio female:male=9:5), all of whom were HLA-B29 positive, with a mean uveitis duration of 55.8 months (range 5–240 months) before MMF or MPS therapy were included. None of the patients had sufficient control of inflammation before initiation of MMF/MPS therapy even despite earlier immunosuppressive treatment (azathioprine n=1 pat., cyclosporine A n=2pat., steroids n=12 pat.). The follow-up consisted of 38.9±22.8 months (at least 6 months). None of the patients had to stop treatment due to side effects. Inflammation was reduced or stabilized in 12 patients (86%) and a steroid-sparing effect was achieved in all of the 12 patients. Average logMAR visual acuity (VA) before starting therapy was 0.36 (right eye) and 0.5 (left eye). Average final logMAR VAs were 0.4 (right eye) and 0.6 (left eye). Visual fields and ERGs were performed regularly over time on 10 of 14 patients; eight of ten patients demonstrated stabilized or even a slightly improvement.

Conclusions: Preservation of visual function is attainable with systemic MMF or MPS medication in patients with BRC. Prompt treatment with these immunosuppressives may offer a good chance for maintaining retinal function.